Vaccination to prevent and treat cervical cancer

This publication has 99 references indexed in Scilit:

• Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer
  New England Journal of Medicine, 2003
• Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C12U] (Ampligen®)
  Vaccine, 2002
• Papillomaviruses and cancer: from basic studies to clinical application
  Nature Reviews Cancer, 2002
• Cancer Immunotherapy Using Sindbis Virus Replicon Particles Encoding a VP22–Antigen Fusion
  Human Gene Therapy, 2002
• Neutralization of Human Papillomavirus Type 11 (HPV‐11) by Serum from Women Vaccinated with Yeast‐Derived HPV‐11 L1 Virus‐like Particles: Correlation with Competitive Radioimmunoassay Titer
  The Journal of Infectious Diseases, 2001
• Genetically modified bone marrow‐derived dendritic cells expressing tumor‐associated viral or “self” antigens induce antitumor immunity in vivo
  European Journal of Immunology, 1997
• Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer
  Vaccine, 1996
• Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective
  JNCI Journal of the National Cancer Institute, 1995
• Identification and characterization of a cDNA clone derived from the Marek's disease tumour cell line RPL1 encoding a homologue of α-transinducing factor (VP16) of HSV-1
  Archiv für die gesamte Virusforschung, 1995
• Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells
  European Journal of Immunology, 1993